Tag: Richard Gaynor

October 20, 2016 Off

FDA approves Lilly’s Lartruv for soft tissue sarcoma treatment

By Dino Mustafić

Eli Lilly and Company announced that FDA has granted approval of LARTRUV (olaratumab injection, 10 mg/mL), in combination with doxorubicin, for the treatment of adults with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.

November 19, 2015 Off

Lilly and Merck move on with oncology clinical trial of and Keytruda

By Dino Mustafić

Eli Lilly and Merck are moving on with an existing oncology clinical trial collaboration to evaluate the safety and efficacy of the combination of Lilly’s Almita (pemetrexed for injection) and Merck’s Keytruda (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).

September 28, 2015 Off

Cyramza Phase II study meets its primary endpoint

By Dino Mustafić

Phase II study of its Cyramza (ramucirumab) in combination with docetaxel met its primary endpoint, demonstrating a statistically significant increase in progression-free survival (PFS) for patients with locally advanced or metastatic urothelial carcinoma who failed prior platinum-based therapy.